CoChat

Long‐term safety and cognitive effects of galantamine in the treatment of probable vascular dementia or Alzheimer's disease with cerebrovascular disease

Kurz, A. F., Erkinjuntti, T., Small, G. W., Lilienfeld, S., Damaraju, C. R. Venkata · 2003 · European Journal of Neurology
Cited by 54

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

The relationship between cholinergic dysfunction and cognitive and functional impairment in patients with vascular dementia (VaD) and Alzheimer's disease (AD) with cerebrovascular disease (CVD) suggests a potential role for cholinomimetic therapy. Initial studies of galantamine demonstrated cognitive, behavioral, and functional benefits in these populations. 326 patients with VaD or AD with CVD who completed an initial 12‐month trial were treated with galantamine 24 mg/day in a 24‐month, open‐label extension. This interim analysis was performed at month 12 of the open‐label extension (248 completed the trial). Galantamine (up to 24 months total) was well tolerated in both groups. The most frequently reported adverse events, characteristic of older dementia patients, included depression, agitation, and insomnia. Gastrointestinal adverse events were less common than initially, indicating declining incidence with long‐term therapy. Patients taking galantamine for the entire study demonstrated the least cognitive decline on AD Assessment Scale‐cog/11: 2.7 points vs. 3.1 points in those given placebo initially (P < 0.001 and P = 0.003, respectively). The long‐term benefits of galantamine were evident in both groups; cognitive baseline levels were maintained for approximaely 21 months in VaD patients and for 12 months in patients with AD with CVD. Long‐term (up to 24 months) galantamine therapy in patients with VaD and AD with CVD is well tolerated and associated with prolonged maintenance of cognitive function.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1468-1331.2003.00677.x

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 54

Metadata

Authors
Kurz, A. F., Erkinjuntti, T., Small, G. W., Lilienfeld, S., & Damaraju, C. R. V.
Venue
European Journal of Neurology
Publisher
Wiley
Published
2003-10-22
Volume
10
Issue
6
Pages
633-640
ISSN
  • 1351-5101 (ISSN-L)
  • 1468-1331
OpenAlex
W2065735162
Cited by
54
References
6
FWCI
4.67
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long‐term safety and cognitive effects of galantamine in the treatment of probable vascular dementia or Alzheimer's disease with cerebrovascular disease. https://app.cochat.ai/papers/10.1046/j.1468-1331.2003.00677.x
The paper
Kurz, A. F., Erkinjuntti, T., Small, G. W., Lilienfeld, S., & Damaraju, C. R. V. (2003). Long‐term safety and cognitive effects of galantamine in the treatment of probable vascular dementia or Alzheimer's disease with cerebrovascular disease. European Journal of Neurology. https://doi.org/10.1046/j.1468-1331.2003.00677.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.